All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Differentiated thyroid cancer (DTC) is the most common endocrine cancer worldwide, and incidence of this cancer, especially of the papillary carcinoma (PTC) type, has been increasing for several decades \[[@pone.0204668.ref001]--[@pone.0204668.ref005]\]. To a large extent, this increase is related to better access to modern diagnostic imaging and biopsies, which contribute to improved detection of early stages of PTC that might have remained undiagnosed in the past \[[@pone.0204668.ref005]--[@pone.0204668.ref009]\]. However, some authors report an increase in the number of invasive, large, or small thyroid cancers \[[@pone.0204668.ref002], [@pone.0204668.ref010]--[@pone.0204668.ref012]\], which suggests a real increase in the incidence of thyroid cancer. Improvements in the quality of imaging studies alone cannot explain the increased incidence of DTC. Genetic and environmental factors, such as exposure to ionizing radiation and iodine consumption, as well as factors associated with lifestyle, are also associated with the increase in cancer incidence \[[@pone.0204668.ref013]--[@pone.0204668.ref015]\].

Obesity is one of the most common public health problems worldwide, and its incidence has been increasing steadily over the past two decades in both developed and developing countries \[[@pone.0204668.ref016]\]. In Poland in the last decade, the percentage of obese adults has increased by 7%, and is similar to the percentage of obese Caucasian adults in the United States \[[@pone.0204668.ref017]\]. Epidemiological data confirm that obesity is independently associated with an increased incidence of various solid tumors, including DTC \[[@pone.0204668.ref018]--[@pone.0204668.ref022]\], but at the same time, there are studies that show no connection between obesity and thyroid cancer \[[@pone.0204668.ref023]--[@pone.0204668.ref025]\]. Links between obesity and predictors of thyroid cancer are also uncertain \[[@pone.0204668.ref026], [@pone.0204668.ref027]\]. Despite the existence of studies demonstrating the impact of obesity on thyroid cancer, no clear mechanism explaining the link has been shown. It has been hypothesized that potential mediators may include insulin, IGF-1, cytokines, inflammation, TSH, adiponectins, leptin, and estrogens \[[@pone.0204668.ref015], [@pone.0204668.ref028], [@pone.0204668.ref029]\].

We sought to analyze the relationship between body mass index (BMI) and clinical and pathological characteristics increasing the risk of poor clinical course, primary treatment response, and outcome of the disease in DTC patients treated in one center in Poland.

Materials and methods {#sec007}
=====================

Patients and study design {#sec008}
-------------------------

A retrospective analysis was performed of the medical records of 2100 Caucasian patients with DTC who had undergone total thyroidectomy or lobectomy at a single center during the years 2000--2016. The following data were obtained: BMI at the time of surgery, prognostic clinicopathological features (sex, age at diagnosis, tumor diameter, multifocality, lymph node metastasis, and extrathyroidal extension), response to primary treatment, and clinical outcome of disease (remission, recurrence, or death). Patients who did not have complete BMI data, patients with a follow-up period of less than 12 months, and patients whose anti-thyroglobulin antibody (TgAb) levels were monitored with an anti-thyroglobulin (Tg) recovery test rather than a direct measurement of antibodies were excluded. The study ultimately included 1181 patients.

Postoperative Tumor Node Metastasis (TNM) staging of all included patients was re-classified according to the most recent 8^th^ edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system and the ATA-modified initial risk stratification system (low, intermediate, and high risk of recurrence) \[[@pone.0204668.ref030], [@pone.0204668.ref031]\]. At the stage of diagnosis, clinicopathological features pNx and Mx were analyzed in detail. Subsequently pNx was clinically reclassified as N0b or N1, while Mx was reclassified as 0 or 1, according to the 8^th^ edition of the AJCC/UICC TNM staging system. All suspicious changes in Nx observed in postoperative ultrasound were verified by fine-needle biopsy with the evaluation of Tg from the aspirate, as described previously \[[@pone.0204668.ref032]\].

Summary of the course of the disease in the present study was dated December 31, 2016; in the case of patients who died prior to this date (22/1181, 1.9%), the state of follow-up was summarized according to the condition of the disease at the time of death.

The study plan was accepted by the Bioethics Committee at the Holycross Chamber of Physicians in Kielce, Poland. It was not necessary to obtain written informed consent from patients because the data was retrospectively obtained from patients' medical history collected during routine diagnostic procedures during hospitalization. All patient records and information were anonymized and de-identified prior to analysis.

Treatment protocol and patient monitoring {#sec009}
-----------------------------------------

All patients included in the study were subjected to primary surgical treatment. The scope of surgery included lobectomy, total thyroidectomy (TT), or total thyroidectomy with central compartment lymphadenectomy. In our center, total thyroidectomy with central compartment lymphadenectomy was performed if the primary tumors were \>10 mm, multiple or bilateral, or extrathyroidal, or when metastases to the lymph nodes (LN) of the central neck compartment were detected during pre-operative evaluation or surgery. We routinely performed central compartment node dissection on the primary tumor side. On the other hand, we performed bilateral central compartment node dissection when the tumor was bilateral or the LNs were enlarged on the opposite side, as demonstrated during pre-operative staging or surgery. However, the decision to remove lateral LNs depended on the pre- or intra-operative diagnosis of metastases to LNs, or a strong clinical suspicion of their involvement. Lobectomy (total excision of the entire thyroid lobe with isthmus) was performed in patients diagnosed with pre-operative unifocal PTC with a diameter of ≤10 mm, in clinical stage N0 (no lymph node metastases diagnosed in preoperative ultrasound), when there were no evident indications for bilateral surgery in the form of changes visible in the ultrasound in the contralateral lobe, and in patients who had previously undergone lobectomy and were diagnosed with low-risk thyroid cancer. TT without central compartment node dissection was performed in patients with nodular goiter who were diagnosed with PTC ≤10 mm (pT1a) after surgery if they had no evidence of cervical node metastasis in clinical N0 (no LN metastases in postoperative ultrasound) and no distant metastases, and after a careful histopathological examination of the postoperative material to exclude multifocal growth.

All patients with initial postoperative tumor stage higher than pT1aN0-xM0 qualified for radioactive iodine (I-131) treatment with a subsequent suppressive dose of levothyroxine (LT4). The standard procedure, 1100--3700 MBq I-131, was administered depending on the TNM status. Protocols for I-131 treatment and evaluation of the efficacy of primary treatment in patients treated with I-131 in our center have been described previously \[[@pone.0204668.ref033]\]. Evaluation of treatment response was carried out 9--12 months after administration of I-131. As we previously reported, patients with ineffective ablation, defined as focal I-131 uptake in the thyroid bed \>0.1% without any other features of the disease, were treated with a second dose of I-131 and reevaluated after 9--12 months \[[@pone.0204668.ref033]\].

The efficacy of surgical treatment in patients with pT1aN0-xM0 who were not treated with I-131 was assessed based on a clinical examination, neck ultrasound, and levels of Tg and TgAb within 4--6 weeks after surgery, before levothyroxine was administered. Patients who received a TT underwent neck and whole body scans. When the results indicated that the primary surgery was not radical enough, patients were referred to secondary TT. Further tests were carried out every 6--12 months, depending on the risk degree of the clinical course, as previously described \[[@pone.0204668.ref034]\].

Diagnostic tests and imaging {#sec010}
----------------------------

Measurements of TSH, Tg, and TgAb were all performed in the same laboratory. The testing methodology has been described in detail previously \[[@pone.0204668.ref034], [@pone.0204668.ref035]\]. The details of neck ultrasound and whole body scintigraphy procedures in our center have also been reported previously \[[@pone.0204668.ref033], [@pone.0204668.ref034]\].

Assessment of treatment response {#sec011}
--------------------------------

Patients treated with I-131 were assessed for response to initial therapy (surgery with I-131) using criteria proposed by Tuttle et al. \[[@pone.0204668.ref036]\], which were accepted by the ATA \[[@pone.0204668.ref031]\]. The response was classified as excellent, indeterminate, biochemically incomplete, or structurally incomplete. Procedures performed during the follow-up until the end of I-131 treatment and assessment of the response were described previously \[[@pone.0204668.ref033]\]. Patients not treated with I-131 were assessed for response to initial therapy (TT or lobectomy) using criteria proposed by Momesso and Tuttle \[[@pone.0204668.ref037]\]. The response was classified as excellent, indeterminate, biochemically incomplete, or structurally incomplete. Procedures performed during monitoring of the course of the disease from the end of surgical treatment to evaluation of response were described previously \[[@pone.0204668.ref034]\].

Anthropometric measurements {#sec012}
---------------------------

All patients included in the study were measured for height and weight without shoes and outer clothing on the day of surgery. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m^2^). BMI values were stratified according to the World Health Organization (WHO) classification: underweight (BMI, \<18.5 kg/m^2^), normal (BMI, 18.5--24.9 kg/m^2^), overweight (BMI, 25.0--29.9 kg/m^2^), and obese (BMI, ≥30.0 kg/m^2^). Obesity was then further stratified into Grade 1 obesity (BMI, 30--34.9 kg/m^2^), Grade 2 obesity (BMI, 35--39.9 kg/m^2^), and Grade 3 obesity (BMI ≥40 kg/m^2^). The relationship between BMI and clinical and pathological features, the response to primary treatment, and the outcome of the disease (recurrent/persistent disease, death) was analyzed.

Final oncological assessment {#sec013}
----------------------------

Follow-up concluded with an oncological assessment on December 31, 2016. Based on the medical documentation, patients' health was assessed by applying the latest ATA guidelines \[[@pone.0204668.ref031]\] and assigning them to groups: no evidence of disease (NED), recurrent/persistent disease, death from cancer, and death from other causes.

Statistical analyses {#sec014}
--------------------

Basic statistics (mean, standard deviation) were determined for continuous variables (age, BMI, tumor size, years of follow-up). Percentages were determined for discrete and ordinal variables. A t-test was applied for testing differences between means. A chi-square test was used to examine the interrelationship of pairs of features. Logistic regression (univariate and multivariate) analysis was used to examine the dependence of selected clinicopathological features from selected prognostic factors. An odds ratio (OR) with a 95% confidence interval was determined. Kaplan-Meier curves were used to analyze overall survival. P-values \<0.05 were considered statistically significant. All statistical analysis was performed using MedCalc Statistical Software version 17.9.7 (MedCalc Software bvba, Ostend, Belgium; [http://www.medcalc.org](http://www.medcalc.org/); 2017).

Results {#sec015}
=======

Baseline characteristics {#sec016}
------------------------

Clinical and pathological features of patients, tumor staging, ATA Initial Risk Stratification System, category of response and final outcome of the disease are summarized in [Table 1](#pone.0204668.t001){ref-type="table"}. We stratified patients into six groups: underweight (BMI, \<18.5 kg/m^2^), normal weight (BMI, 18.5--24.9 kg/m^2^), overweight (BMI, 25.0--29.9 kg/m^2^), Grade 1 obesity (BMI, 30--34.9 kg/m^2^), Grade 2 obesity (BMI, 35--39.9 kg/m^2^), and Grade 3 obesity (BMI, ≥40 kg/m^2^). The numbers of patients in each group are indicated in [Table 1](#pone.0204668.t001){ref-type="table"}.

10.1371/journal.pone.0204668.t001

###### Characteristics of DTC patients.

![](pone.0204668.t001){#pone.0204668.t001g}

  Feature                                                        Total n = 1181 (100%)
  -------------------------------------------------------------- ------------------------
  Female (F)                                                     1039 (88%)
  Male (M)                                                       142 (12%)
  Mean age at diagnosis                                          51.3 years (SD ± 16.5)
  female                                                         50.1 years (SD ± 17.0)
  male                                                           56.0 years (SD ± 14.2)
  Age group:[\*](#t001fn002){ref-type="table-fn"}                
  \<55 years                                                     682 (57.7%)
  ≥55 years                                                      499 (42.3%)
  Mean BMI                                                       28.1 kg/m^2^ (±5.1)
  Range                                                          16.6--53.2 kg/m^2^
  BMI group:                                                     
  Underweight                                                    8 (0.7%)
  Normal                                                         339 (28.7%)
  Overweight                                                     436 (36.9%)
  BMI obesity group                                              398
  grade 1 (30--34.9)                                             275 (69.1%)
  grade 2 (35--39.9)                                             98 (24.6%)
  grade 3 (≥40)                                                  25 (6.3%)
  Mean tumor size                                                13.2 mm (SD ± 14.9)
  range                                                          0.5 -- 130mm
  Histology:                                                     
  Papillary                                                      1117 (94.6%)
  Follicular                                                     44 (3.7%)
  Hürthle cell                                                   6 (0.5%)
  Poorly differentiated (insular)                                14 (1.2%)
  Papillary cancer histologic subtype:                           
  Classic                                                        920 (82.4%)
  Follicular                                                     173 (15.5%)
  Other, non-aggressive                                          9 (0.8%)
  Other, aggressive [\*\*](#t001fn003){ref-type="table-fn"}      15 (1.3%)
  Extrathyroidal extension:                                      
  Negative                                                       955 (80.9%)
  Microscopic                                                    191 (16.1%)
  Gross                                                          35 (3.0%)
  Vascular invasion:                                             
  No                                                             1111 (94.1%)
  Yes                                                            70 (5.9%)
  Multifocality:                                                 254 (21.5%)
  Tumor stage: [\*](#t001fn002){ref-type="table-fn"}             
  T1                                                             953 (80.8%)
  T2                                                             102 (8.6%)
  T3                                                             108 (9.1%)
  T4                                                             18 (1.5%)
  Tumor diameter:                                                
  ≤ 10 mm                                                        746 (63.2%)
  \> 10 mm                                                       435 (36.8%)
  Including \> 20mm                                              228
  Lymph node metastasis: [\*](#t001fn002){ref-type="table-fn"}   
  N0a                                                            481 (40.7%)
  N0b                                                            563 (47.7%)
  N1                                                             137 (11.6%)
  Distant metastasis:                                            
  M0                                                             1160 (98.2%)
  M1                                                             21 (1.8%)
  TNM Stage: [\*](#t001fn002){ref-type="table-fn"}               
  I                                                              1071 (90.7%)
  II                                                             76 (6.4%)
  III                                                            12 (1.0%)
  IV                                                             22 (1.9%)
  Radioactive iodine (^131^I) therapy:                           
  Yes                                                            821 (69.5%)
  No                                                             360 (30.5%)
  ATA Initial Risk Stratification System:                        
  Low                                                            815 (69.0%)
  Intermediate                                                   312 (26.4%)
  High                                                           54 (4.6%)
  Response to therapy:                                           
  Excellent                                                      991 (83.9%)
  Indeterminate                                                  108 (9.1%)
  Biochemically incomplete                                       27 (2.3%)
  Structurally incomplete                                        55 (4.7%)
  Follow-up:                                                     
  Median and range                                               7.7 years (1--16)
  Final follow-up (December 31, 2016):                           
  NED                                                            1097 (94.7%)
  Structurally persistent disease                                21 (1.8%)
  Biochemically persistent disease                               41 (3.5%)
  Death:                                                         22 (1.9%)
  Tumor- related                                                 13 (1.1%)
  Tumor-unrelated                                                9 (0.8%)

BMI: body mass index (kg/m^2^); SD: standard deviation; NED: no evidence of disease; N0a: one or more cytologically or histologically confirmed benign lymph node; N0b: no radiologic or clinical evidence of locoregional lymph node metastasis; N1: metastasis to regional lymph nodes; ATA: American Thyroid Association.

\* determined by 8^th^ edition of AJCC/UICC TNM staging system

\*\* oxyphilic, diffuse sclerosing, solid

The patients had diseases of differing severities and clinical characteristics, as specified in the [Table 1](#pone.0204668.t001){ref-type="table"}. Histologically, the vast majority of tumors were papillary; in terms of clinical severity, the majority were stage pT1. Most patients received I-131 treatment, at a range of doses (1100--3700 MBq) depending on tumor stage, whereas patients with small tumors without metastasis (pT1aN0-xM0) did not. Most patients (83.9%) responded well to therapy, although 5.3% presented with features of biochemically or structurally persistent disease at the end of follow-up.

Associations between BMI and clinicopathological features of DTC {#sec017}
----------------------------------------------------------------

The clinicopathological features of DTC were evaluated in relation to BMI groups ([Table 2](#pone.0204668.t002){ref-type="table"}). We observed no statistically significant dependence of the primary tumor size, more aggressive DTC histopathologic type or histopathologic PTC subtype, multifocality, extrathyroidal extension (microscopic or gross), vascular invasion, lymph node metastases, distant metastases, intermediate or high risk of recurrence according to ATA, poorer response to primary treatment, or outcome of the disease in relation to BMI (all six groups).

10.1371/journal.pone.0204668.t002

###### Clinicopathologic characteristics according to the six BMI groups.

![](pone.0204668.t002){#pone.0204668.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Feature                                                       Underweight\        Normal\             Overweight\         Grade 1 obesity\    Grade 2 obesity\    Grade 3 obesity BMI ≥ 40\   P-value
                                                                BMI \< 18.5\        18.5 ≤ BMI \< 25\   25 ≤ BMI \< 30\     30 ≤ BMI \< 35\     35 ≤ BMI \< 40\     n = 25                      
                                                                n = 8               n = 339             n = 436             n = 275             n = 98                                          
  ------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- --------------------------- ---------
  Age at diagnosis (mean ± SD)                                  27.8 ± 11.5 years   44.1 ± 14.2 years   52.4 ± 13.2 years   54.3 ± 10.7 years   54.6 ± 11.7 years   52.8 ± 8.9 years            \<0.001

  Age group:[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                               \<0.001

  \<55                                                          8 (100%)            251 (74.0%)         225 (51.6%)         140 (50.9%)         45 (45.5%)          13 (54.2%)                  

  ≥55                                                           0 (0%)              88 (26.0%)          211 (48.4%)         135 (49.1%)         53 (54.5%)          12 (45.8%)                  

  Gender:                                                                                                                                                                                       0.007

      Female                                                    8 (100%)            315 (92.9%)         377 (86.5%)         233 (84.7%)         82 (83.7%)          24 (96%)                    

      Male                                                      0 (0%)              24 (7.1%)           59 (13.5%)          42 (15.3%)          16 (16.3%)          1 (4%)                      

  Tumor size (mm) (mean SD)                                     13.5 ± 11.7         12.6 ± 14.9         12.5 ± 13.5         14.5 ± 16.2         14.6 ± 17.8         10.2 ± 6.6                  0.383

  Tumor size \>10mm                                                                                                                                                                             0.679

  Yes                                                           4 (50.0%)           118 (34.8%)         156 (35.8%)         110 (40.0%)         36 (36.7%)          11 (44.0%)                  

  No                                                            4 (50.0%)           221 (65.2%)         280 (64.2%)         165 (60.0%)         62 (63.3%)          14 (56.0%)                  

  Tumor size \>20mm                                                                                                                                                                             0.694

  Yes                                                           1 (12.5%)           63 (18.6%)          84 (19.3%)          58 (21.1%)          20 (20.4%)          2 (8.0%)                    

  No                                                            7 (87.5%)           276 (81.4%)         352 (80,7%)         217 (78.9%)         78 (79.6%)          23 (92.0%)                  

  Histology:                                                                                                                                                                                    0.966

  Papillary                                                     8 (100%)            321 (94.7%)         413 (94.7%)         261 (94.9%)         89 (90.9%)          25 (100%)                   

  Follicular                                                    0 (0%)              13 (3.8%)           17 (3.9%)           8 (2.9%)            6 (6.1%)            0 (0%)                      

  Hürthle cell                                                  0 (0%)              2 (0.6%)            2 (0.5%)            1 (0.4%)            1 (1.0%)            0 (0%)                      

  Poorly differentiated (insular)                               0 (0%)              3 (0.9%)            4 (0.9%)            5 (1.8%)            2 (2.0%)            0 (0%)                      

  PTC histologic subtype:                                       \                   \                   \                   \                   \                   \                           \
                                                                                                                                                                                                0.828

  Classic                                                       6 (75%)             254 (79.1%)         343 (83.1%)         215 (82.4%)         80 (89.9%)          22 (88%)                    

  Follicular                                                    2 (25%)             59 (18.4%)          63 (15.3%)          39 (14.9%)          7 (7.9%)            3 (12%)                     

  Other, non-aggressive                                         0 (0%)\             4 (1.2%)\           2 (0.5%)\           2 (0.8%)\           1 (1.1%)\           0 (0%)\                     

  Other, aggressive[\*\*](#t002fn003){ref-type="table-fn"}      0 (0%)              4 (1.2%)            5 (1.2%)            5 (1.9%)            1 (1.1%)            0 (0%)                      

  Multifocality:                                                                                                                                                                                0.164

  Yes                                                           1 (12.5%)           63 (18.6%)          89 (20.4%)          75 (27.3%)          21 (21.4%)          5 (20.0%)                   

  No                                                            7 (87.5%)           276 (81.4%)         347 (79.6%)         200 (72.7%)         77 (78.6%)          20 (80.0%)                  

  Extrathyroidal extension:                                     \                   \                   \                   \                   \                   \                           0.608

  Negative                                                      7 (87.5%)           287 (84.6%)         347 (79.5%)         216 (78.5%)         76 (77.6%)          22 (88%)                    

  Microscopic                                                   1 (12.5%)           43 (12.7%)          77 (17.7%)          50 (18.2%)          17 (17.3%)          3 (12%)                     

  Gross                                                         0 (0%)              9 (2.7%)            12 (2.8%)           9 (3.3%)            5 (5.1%)            0 (0%)                      

  Vascular invasion:                                                                                                                                                                            0.411

  No                                                            8 (100%)            322 (95.0%)         403 (92.4%)         261 (94.9%)         92 (93.9%)          25 (100%)                   

  Yes                                                           0 (0%)              17 (5.0%)           33 (7.6%)           14 (5.1%)           6 (6.1%)            0 (0%)                      

  Tumor stage:[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                             0.814

  T1                                                            7 (87.5%)           281 (82.9%)         349 (80.0%)         214 (77.8%)         79 (80.6%)          23 (92.0%)                  

  T2                                                            1 (12.5%)           26 (7.7%)           42 (9.6%)           27 (9.8%)           5 (5.1%)            1 (4.0%)                    

  T3                                                            0 (0%)              27 (8.0%)           39 (8.9%)           28 (10.2%)          13 (13.3%)          1 (4.0%)                    

  T4                                                            0 (0%)              5 (1.5%)            6 (1.4%)            6 (2.2%)            1 (1.0%)            0 (0.0%)                    

  Lymph node metastasis:[\*](#t002fn002){ref-type="table-fn"}   \                   \                   \                   \                   \                   \                           0.512\

  No (N0a or N0b)                                               7 (87.5%)           297 (87.6%)         387 (88.8%)         244 (88.7%)         84 (85.7%)          25 (100%)                   

  Yes (N1)                                                      1 (12.5%)           42 (12.4%)          49 (11.2%)          31 (11.3%)          14 (14.3%)          0 (0.0%)                    

  Distant metastasis:                                                                                                                                                                           0.965

  M0                                                            8 (100%)            333 (98.2%)         429 (98.4%)         269 (97.8%)         96 (98.0%)          25 (100%)                   

  M1                                                            0 (0.0%)            6 (1.8%)            7 (1.6%)            6 (2.2%)            2 (2.0%)            0 (0.0%)                    

  TNM stage:[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                               0.140

  I                                                             8 (100%)            323 (95.3%)         393 (90.1%)         240 (87.3%)         83 (84.8%)          24 (96.0%)                  

  II\                                                           0 (0.0%)\           9 (2.7%)\           29 (6.7%)\          25 (9.1%)\          12 (12.2%)\         1 (4.0%)\                   
  III                                                           0 (0.0%)            3 (0.9%)            5 (1.1%)            3 (1.1%)            1 (1.0%)            0 (0.0%)                    

  IV                                                            0 (0.0%)            4 (1.2%)            9 (2.1%)            7 (2.5%)            2 (2.0%)            0 (0.0%)                    

  Radioactive iodine therapy                                    \                   \                   \                   \                   \                   \                           0.667

  Yes                                                           5 (62.5%)           224 (66.1%)         306 (70.2%)         198 (72.0%)         70 (71.4%)          18 (72.0%)                  

  No                                                            3 (37.5%)           115 (33.9%)         130 (29.8%)         77 (28.0%)          28 (28.6%)          7 (28.0%)                   

  ATA Initial Risk Stratification System                        \                   \                   \                   \                   \                   \                           \
                                                                                                                                                                                                0.489

  Low                                                           6 (75.0%)           241 (71,1%)         302 (69.2%)         181 (65.8%)         63 (64.3%)          22 (88.0%)                  

  Intermediate                                                  2 (25.0%)           86 (25.4%)          115 (26.4%)         77 (28.0%)          29 (29.6%)          3 (12.0%)                   

  High                                                          0 (0.0%)            12 (3.5%)           19 (4.4%)           17 (6.2%)           6 (6.1%)            0 (0.0%)                    

  Response to therapy:                                          \                   \                   \                   \                   \                   \                           0.389\

  Excellent                                                     7 (87.5%)           288 (85.0%)         363 (83.3%)         235 (85.5%)         74 (75.5%)          24 (96.0%)                  

  Indeterminate                                                 0 (0.0%)            29 (8.5%)           41 (9.3%)           22 (8.0%)           15 (15.3%)          1 (4.0%)                    

  Biochemically incomplete                                      1 (12.5%)\          6 (1.8%)\           9 (2.1%)\           8 (2.9%)\           3 (3.1%)\           0 (0.0%)\                   

  Structurally incomplete                                       0 (0.0%)            16 (4.7%)           23 (5.3%)           10 (3.6%)           6 (6.1%)            0 (0.0%)                    

  Status of final follow-up:                                    \                   \                   \                   \                   \                   \                           \
                                                                                                                                                                                                0.440

  Remission (NED)                                               7 (87.5%)           321 (95.5%)         400 (93.7%)         259 (95.6%)         86 (92.5%)          24 (100.0%)                 

  Recurrent/persistent disease                                  1 (12.5%)           15 (4.5%)           27 (6.3%)           12 (4.4%)           7 (7.5%)            0 (0.0%)                    

  Death                                                         0                   3                   9                   4                   5                   1                           0.574

  Cancer-related                                                0 (0.0%)            2 (66.7%)           6 (66.7%)           3 (75.0%)           2 (40.0%)           0 (0.0%)                    

  Cancer-unrelated                                              0 (0.0%)            1 (33.3%)           3 (33.3%)           1 (25.0%)           3 (60.0%)           1 (100.0%)                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index (kg/m^2^); SD: standard deviation; NED: no evidence of disease; ATA: American Thyroid Association; PTC: papillary thyroid cancer; N0a: one or more cytologically or histologically confirmed benign lymph node; N0b: no radiologic or clinical evidence of locoregional lymph node metastasis; N1: metastasis to regional lymph nodes)

\**determined by 8*^*th*^ *edition of AJCC/UICC TNM staging system*

*\*\*oxyphilic*, *diffuse sclerosing*, *solid*

We observed a statistically significant relationship between sex and BMI (p = 0.007), and age and BMI (\<55 years vs. ≥55 years) (p \<0.001) was found. In this study population, obesity was significantly (p = 0.035) more prevalent in men (59/142; 41.5%) than in women (339/1039; 32.5%) ([S1 Table](#pone.0204668.s001){ref-type="supplementary-material"}). According to the updated 8^th^ edition of AJCC/TNM staging system, BMI was not significantly associated with more advanced TNM stage in patients \<55 years of age (stage I vs. stage II) (p = 0.266) or ≥55 years of age (stage I-II vs. III-IV) (p = 0.877) ([S1 Dataset](#pone.0204668.s003){ref-type="supplementary-material"}).

Predictive factors for aggressive pathology, response to therapy, and outcome of DTC {#sec018}
------------------------------------------------------------------------------------

We performed logistic regression analysis (univariate and multivariate) to determine the dependence of selected features of pathological aggressiveness of cancer \[extrathyroidal extension, lymph node metastasis, distant metastases, and ATA Initial Risk Stratification System score (high and intermediate), treatment response, and disease outcome\] on prognostic factors such as age, sex, tumor size, multifocality, and BMI ([Table 3](#pone.0204668.t003){ref-type="table"}). In the univariate analysis, many prognostic factors apart from BMI had a significant impact on the analyzed clinical features. In multivariate analysis of BMI (all six groups), there was no statistically significant relationship to pathological aggressiveness (i.e. extrathyroidal extension, lymph node metastases, or distant metastases).

10.1371/journal.pone.0204668.t003

###### Predictive factors for aggressive pathologic features, response to therapy, and outcome of DTC, as defined by multiple logistic regression analysis.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                            Logistic regression model                                  
  ----------------------------------------------------------------------------------------- --------------------------- --------- -------------------- ---------
  Extrathyroidal extension:                                                                                                                            

  Age (years)                                                                               1.02 (1.01--1.03)           0.001     1.01 (1.00--1.02)    0.024

  Male gender                                                                               1.45 (0.96--2.19)           0.076     1.21 (0.76--1.90)    0.418

  Tumor size (mm)                                                                           1.04 (1.03--1.04)           \<0.001   1.03 (1.03--1.04)    \<0.001

  Multifocality                                                                             1.93 (1.39--2.67)           0.001     2.02 (1.44--2.84)    \<0.001

  BMI groups                                                                                1.12 (0.97--1.28)           0.121     1.03 (0.88--1.21)    0.712

  Lymph node metastasis:[\*](#t003fn002){ref-type="table-fn"}                                                                                          

  Age (years)                                                                               0.97 (0.96--0.98)           \<0.001   0.96 (0.94--0.97)    \<0.001

  Male gender                                                                               2.72 (1.75--4.22)           \<0.001   2.29 (1.39--3.77)    0.002

  Tumor size (mm)                                                                           1.03 (1.02--1.04)           \<0.001   1.04 (1.03--1.05)    \<0.001

  Multifocality                                                                             1.66 (1.12--2.47)           0.011     2.22 (1.45--3.40)    0.003

  BMI groups                                                                                0.95 (0.79--1.23)           0.524     1.05 (0.86--1.28)    0.635

  Distant metastases:                                                                                                                                  

  Age (years)                                                                               1.02 (0.99--1.06)           0.167     1.01 (0.97--1.05)    0.604

  Male gender                                                                               3.01 (1.15--7.89)           0.025     1.46 (0.42--4.99)    0.552

  Tumor size (mm)                                                                           1.05 (1.03--1.06)           \<0.001   1.04 (1.03--1.06)    \<0.001

  Multifocality                                                                             0.60 (0.18--2.06)           0.421     0.86 (0.24--3.12)    0.819

  BMI groups                                                                                1.03 (0.67--1.56)           0.896     0.94 (0.56--1.59)    0.832

  ATA risk of recurrence (high and intermediate)                                                                                                       

  Age (years)                                                                               1.00 (0.99--1.01)           0.292     0.99 (0.98--1.01)    0.827

  Male gender                                                                               2.07 (1.45--2.95)           0.001     1.67 (1.12--2.46)    0.023

  Tumor size (mm)                                                                           1.07 (1.06--1.09)           \<0.001   1.07 (1.06--1.09)    \<0.001

  Multifocality                                                                             1.54 (0.16--2.06)           0.003     1.73 (1.26--2.38)    0.008

  BMI groups                                                                                1.04 (0.92--1.17)           0.506     0.98 (0.85--1.14)    0.843

  Response to therapy (indeterminate, biochemically incomplete, structurally incomplete):   \                           \         \                    \

      Age (years)\                                                                          1.00 (0.99--1.02)\          0.413\    1.00 (0.99--1.01)\   0.907\
  Male gender                                                                               2.23 (1.48--3.34)           0.001     1.74 (1.12--2.72)    0.014

      Tumor size (mm)                                                                       1.03 (1.02--1.04)           \<0.001   1.03 (1.02--1.04)    \<0.001

      Multifocality                                                                         1.16 (0.80--1.68)           0.426     1.21 (0.82--1.78)    0.323

      BMI groups                                                                            1.04 (0.89--1.21)           0.573     1.01 (0.86--1.19)    0.905

  Status of final follow-up (persistent disease; deaths):                                                                                              

  Age (years)                                                                               1.04 (1.02--1.06)           0.001     1.03 (1.01--1.05)    0.007

  Male gender                                                                               2.31 (1.34--3.99)           0.003     1.30 (0.66--2.56)    0.445

  Tumor size (mm)                                                                           1.05 (1.04--1.06)           \<0.001   1.05 (1.04--1.06)    \<0.001

  Multifocality                                                                             1.24 (0.74--2.06)           0.419     1.32 (0.75--2.33)    0.340

  BMI groups                                                                                1.12 (0.91--1.38)           0.297     0.92 (0.71--1.95)    0.534
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

ATA: American Thyroid Association; OR: odds ratio; CI: confidence interval; BMI groups: group 1 (underweight; BMI, \<18.5 kg/m^2^), group 2 (normal; BMI, 18.5--24.9 kg/m^2^), group 3 (overweight; BMI, 25.0--29.9 kg/m^2^), group 4 (Grade 1 obesity; BMI, 30--34.9 kg/m^2^), group 5 (Grade 2 obesity; BMI, 35--39.9 kg/m^2^), group 6 (Grade 3 obesity; BMI, \>40 kg/m^2^).

*\*determined by 8*^*th*^ *edition of AJCC/UICC TNM staging system*

Prognostic factors for extrathyroidal extension were tumor size and multifocality. Prognostic factors for lymph node metastases were age, male gender, tumor diameter, and multifocality. The only prognostic factor for distant metastases was tumor diameter.

BMI was not a statistically significant predictive factor, in contrast to tumor size and multifocality, which were prognostic factors for intermediate and high recurrence risk according to the ATA system. In addition, according to the multivariate logistic regression analysis, BMI was not a predictor of microscopic or gross extrathyroidal extension, either in BMI groups or when BMI was considered as a continuous variable ([Table 4](#pone.0204668.t004){ref-type="table"}). Likewise, BMI was not a statistically significant prognostic factor for poorer clinical response to the primary treatment (indeterminate, biochemically or structurally incomplete) or disease outcome (persistent/recurrent disease or death from cancer) ([Table 3](#pone.0204668.t003){ref-type="table"}).

10.1371/journal.pone.0204668.t004

###### Multivariate logistic regression analyses, using BMI groups and BMI as a continuous variable.

![](pone.0204668.t004){#pone.0204668.t004g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------
                                 \                   Microscopic extrathyroidal extension   Gross extrathyroidal extension                       
                                 Predictors\                                                                                                     
  ------------------------------ ------------------- -------------------------------------- -------------------------------- ------------------- -------
  BMI groups                     Age (years)         1.01 (0.99--1.02)                      0.200                            1.05 (1.02--1.09)   0.003

  Male gender                    1.12 (0.68--1.83)   0.652                                  1.90 (0.74--4.89)                0.184               

  Tumor size (mm)                1.03 (1.02--1.04)   \<0.001                                1.06 (1.04--1.07)                \<0.001             

  Multifocality                  2.17 (1.52--3.08)   \<0.001                                1.49 (0.60--3.68)                0.391               

  BMI                            1.04 (0.88--1.23)   0.616                                  0.95 (0.64--1.43)                0.823               

  BMI as a continuous variable   Age (years)         1.01 (1.00--1.02)                      0.195                            1.05 (1.02--1.09)   0.003

  Male gender                    1.12 (0.68--1.83)   0.643                                  1.89 (0.73--4.86)                0.187               

  Tumor size (mm)                1.03(1.02--1.04)    \<0.001                                1.06 (1.04--1.07)                \<0.001             

  Multifocality                  2.17 (1.52--3.08)   \<0.001                                1.49 (0.60--3.68)                0.388               

  BMI                            1.01 (0.97--1.04)   0.701                                  0.95 (0.91--1.07)                0.742               
  ------------------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; CI: confidence interval; BMI groups: group 1 (underweight; BMI, \<18.5 kg/m^2^), group 2 (normal; BMI, 18.5--24.9 kg/m^2^), group 3 (overweight; BMI, 25.0--29.9 kg/m^2^), group 4 (Grade 1 obesity; BMI, 30--34.9 kg/m^2^), group 5 (Grade 2 obesity; BMI, 35--39.9 kg/m^2^), group 6 (Grade 3 obesity; BMI, \>40 kg/m^2^).

By contrast, male sex and tumor size were associated with worse response to treatment (indeterminate, biochemically or structurally incomplete), and age and tumor size were prognostic factors for disease outcome (persistent/recurrent disease or death from cancer) ([Table 3](#pone.0204668.t003){ref-type="table"}).

Overall survival according to BMI group {#sec019}
---------------------------------------

Median duration of the follow-up of the studied group was 7.7 years (range, 1--16 years). The overall survival was compared between groups using the log-rank test ([Fig 1](#pone.0204668.g001){ref-type="fig"}, [Table 5](#pone.0204668.t005){ref-type="table"}). Overall survival did not differ significantly according to BMI (all six groups).

![Comparison of overall survival according to BMI group.\
No significant differences were detected among individuals in the underweight (BMI \< 18.5), normal body weight (18.5 ≤ BMI \< 25), overweight (25 ≤ BMI \< 30), grade 1 obese (30 ≤ BMI \< 35), grade 2 obese (35 ≤ BMI \< 40), or grade 3 obese (BMI ≥ 40) groups (p = 0.7723).](pone.0204668.g001){#pone.0204668.g001}

10.1371/journal.pone.0204668.t005

###### Comparison of survival curves.
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  -----------------------------------------------------------------------------------------------------------------------------------------
  Survival time (years)                BMI \< 18.5\   18.5 ≤ BMI \< 25\   25 ≤ BMI \< 30\   30 ≤ BMI \< 35\   35 ≤ BMI \< 40\   BMI ≥ 40\
                                       n = 8          n = 339             n = 436           n = 275           n = 98            n = 25
  ------------------------------------ -------------- ------------------- ----------------- ----------------- ----------------- -----------
  5                                    100%           100%                99.7%             99.2%             98.0%             100%

  10                                   100%           98.5%               97.3%             99.2%             95.2%             100%

  15                                   100%           96.5%               93.6%             97.5%             95.2%             100%

  P-value for log-rank test = 0.7723                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------

Discussion {#sec020}
==========

Obesity is a serious global health problem, especially in developed countries, and its prevalence is increasing. It is the cause of many chronic diseases and has been linked to some types of cancer \[[@pone.0204668.ref038]--[@pone.0204668.ref040]\]. It has been posited that thyroid cancer is related to obesity \[[@pone.0204668.ref018]\], and the rise in the number of new thyroid cancer cases in recent decades may be due in part to the increased prevalence of obesity \[[@pone.0204668.ref021], [@pone.0204668.ref041]--[@pone.0204668.ref043]\]. However, a causal link between obesity and thyroid cancer is not widely accepted. A retrospective study of fine-needle aspiration biopsies of 4849 thyroid nodules showed no relationship between obesity and cancer risk; the incidence of suspicious or malignant nodules did not differ between five BMI groups (normal body weight, overweight, and Grade 1--3 obesity) \[[@pone.0204668.ref044]\]. Similarly, no association was found between obesity and thyroid cancer in a study of people undergoing preventive screening for various risk factors for thyroid cancer \[[@pone.0204668.ref045]\], nor in one other cohort study \[[@pone.0204668.ref024], [@pone.0204668.ref046]\].

In addition to studies on the association of obesity with the incidence of thyroid cancer, several studies have investigated the role of obesity in the aggressiveness of the course of the disease. The results of these studies are mixed, with some studies showing a positive relationship \[[@pone.0204668.ref047]--[@pone.0204668.ref050]\] and others showing no relationship \[[@pone.0204668.ref026], [@pone.0204668.ref027], [@pone.0204668.ref051]\]. In the current study of patients with DTC, there was no relationship between BMI and aggressive clinicopathological features, the degree of clinical progression, the response to primary treatment, or the outcome of the disease. In addition, BMI was not a significant predictor of high or intermediate risk of recurrence according to the ATA Risk Stratification system, as reported by Grani et al. \[[@pone.0204668.ref052]\]. Our results are in line with those of Kwon et al. \[[@pone.0204668.ref051]\], in which the authors did not find any association between BMI and clinicopathological features of thyroid cancer or disease outcome. Kim et al. reported that there was no independent association between BMI and stage of PTC at diagnosis \[[@pone.0204668.ref027]\]. Paes et al. showed no relationship between BMI and aggressive clinicopathological features of thyroid cancer or disease outcome (recurrent/persistent disease) \[[@pone.0204668.ref026]\]. In the Paes et al. study, the majority of patients were Caucasian (93%), with a median BMI of 27.8 kg/m^2^ \[[@pone.0204668.ref026]\]. In the present study, the median BMI was similar (28.1 kg/m^2^), and all patients included in the study were Caucasian. By contrast, Kim et al. showed that higher BMI was significantly associated with large tumor size, extrathyroidal extension, and more advanced stage of cancer \[[@pone.0204668.ref048]\]. In the Kim et al. study, median BMI was 23.8 kg/m^2^ and all patients were Korean. As in the Paes et al. and Kim et al. studies \[[@pone.0204668.ref026], [@pone.0204668.ref048]\], no correlation was found between higher BMI and recurrent/persistent disease, despite differences in clinicopathological features that are known prognostic factors for DTC. Discrepancies between the results of these studies probably arise from the number of obese patients (BMI ≥30 kg/m^2^) enrolled in each study; 101/259 (38.9%) patients in the Paes et al. study were obese, and 398/1181 patients (33.7%) were obese in the present study \[[@pone.0204668.ref026]\], but only 95/2057 (4.6%) patients in the Kim et al. study were obese \[[@pone.0204668.ref048]\]. Findings consistent with those of Kim et al. were also obtained in studies performed in China \[[@pone.0204668.ref048], [@pone.0204668.ref053], [@pone.0204668.ref054]\]. Paes et al., like the present study, lacked data on such parameters as TSH, fasting glucose, and total cholesterol \[[@pone.0204668.ref026]\]. The composition of our study population was similar in race and range of obesity to that of the Paes et al. study, which may contribute to the similarity of our research results \[[@pone.0204668.ref026]\]. Differences pertaining to the small number of obese Asians may result from specific ethnic features of this group. Asians are typically of shorter height and less obese, and their typical diet differs from that of Caucasians \[[@pone.0204668.ref049]\]. Differences may also result from the type of obesity, duration of obesity, and differences in physical activity. Moreover, the use of the same WHO classification for the Caucasian and Asian populations, as well as the difference in BMI distributions, may be responsible for the conflicting results \[[@pone.0204668.ref054]\]. These features may explain, among others, discrepancies regarding the relationship between BMI and prognostic factors for thyroid cancer. Consequently, the relationship between BMI and clinicopathological features of thyroid cancer remains controversial.

Another factor that should be taken into account when considering the role of obesity in thyroid cancer is the potential for a delay in diagnosis due to difficulties in detecting thyroid nodules during neck examinations of obese patients. Although the present study and others did not find increased BMI to be associated with larger tumor \[[@pone.0204668.ref026], [@pone.0204668.ref051], [@pone.0204668.ref052]\], other studies have observed this trend \[[@pone.0204668.ref047], [@pone.0204668.ref048], [@pone.0204668.ref055]\]. Additionally, Tresallet et al. reported that obese patients with PTC \>10 mm had an increased risk of persistent / recurrent disease (OR = 3.8, 95% CI: 1.6--8.8; p = 0.03)\[[@pone.0204668.ref055]\]. However, in this study and in Chung et al. and Kwon et al., no such relationship was observed \[[@pone.0204668.ref051], [@pone.0204668.ref056]\]. In our study, we analyzed the effects of tumor diameter \> 10 mm and the tumor diameter considered as a continuous variable on disease outcome in patients with BMI \<30 kg/m^2^ and BMI ≥30 kg/m^2^. We observed an increased risk of persistent/recurrent disease in patients with tumor diameter \>10 mm, and as a function of tumor diameter when used as a continuous variable in both groups ([S2 Table](#pone.0204668.s002){ref-type="supplementary-material"}). Thus, the size of the tumor itself, in both obese and non-obese patients, is a strong prognostic factor affecting disease outcome.

In univariate and multivariate analysis, higher BMI was not a predictor of aggressive clinicopathological features of DTC \[extrathyroidal extension (microscopic or gross), lymph node metastases, and distant metastases\]. Many studies report that BMI is a predictor of microscopic extrathyroidal extension, but our findings and those of Kwon et al. do not confirm this conclusion \[[@pone.0204668.ref048], [@pone.0204668.ref052]--[@pone.0204668.ref054], [@pone.0204668.ref057]\]. In our study, tumor size and multifocality were prognostic factors for microscopic extrathyroidal extension. According to the 8^th^ edition of AJCC/TNM staging system, microscopic extrathyroidal extension does not affect cancer stage \[[@pone.0204668.ref058]\]. Also, higher BMI was not a prognostic factor for a poorer treatment response (indeterminate, biochemically incomplete, or structurally incomplete), nor for a worse outcome of the disease (persistent/recurrent disease or death from cancer). Our results agree with those of Chung et al. \[[@pone.0204668.ref056]\], in which the authors did not find a significant difference between BMI groups in the outcome of the disease. They found that BMI was not a prognostic factor for PTC, which we also found in the present study.

We investigated the relationship between BMI and the survival of DTC patients and found that there was no significant difference in the overall survival of patients in relation to BMI groups. These results are in line with those of Yousif Al-Ammar et al. \[[@pone.0204668.ref059]\].

This retrospective study has several strengths. Firstly, it contains a large, ethnically homogeneous ethnic group of patients diagnosed and treated at a single center in Poland, in accordance with current guidelines for thyroid cancer. Secondly, this study included a larger group of obese patients (398 obese out of a total 1181 patients) than previous studies, with more Grade 2 and Grade 3 obese patients (BMI, ≥35 kg/m^2^; n = 123) \[[@pone.0204668.ref026], [@pone.0204668.ref048], [@pone.0204668.ref052], [@pone.0204668.ref055]\]. Because of this, we were able to perform separate analysis of six different BMI groups for the first time. Lastly, our follow-up period was approximately 7.7 years, similar to that in the work of Kwon et al. (approximately 8.4 years), and longer than those of several other studies \[[@pone.0204668.ref026], [@pone.0204668.ref051], [@pone.0204668.ref055], [@pone.0204668.ref056]\].

This work also has some limitations. Firstly, because this was a retrospective study, no information was available regarding the duration of obesity and thyroid cancer, waist-to-hip ratio, body fat percentage, skin fold thickness, and abdominal fat evaluation. Thus, this study defined obesity based solely on BMI, similar to many other studies \[[@pone.0204668.ref026], [@pone.0204668.ref048], [@pone.0204668.ref049], [@pone.0204668.ref051], [@pone.0204668.ref052], [@pone.0204668.ref055], [@pone.0204668.ref056]\]. For most patients, there was no information regarding TSH at the time of the cancer diagnosis available, so the relationship between TSH and thyroid status at the time of the diagnosis could not be assessed. There was also no detailed information on comorbidities such as diabetes, insulin resistance, and hypercholesterolemia, or lifestyle factors such as nutrition, smoking, alcohol consumption, and physical activity.

In conclusion, obesity was not associated with more aggressive clinicopathological features of thyroid cancer in our study. Obesity was not a risk factor for more advanced stages of cancer, nor was it a prognostic factor for poorer treatment response or worse clinical outcome in DTC patients.
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